MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price traded down 9.4% during trading on Thursday . The stock traded as low as GBX 230 ($2.98) and last traded at GBX 240 ($3.10). 86,242 shares were traded during trading, an increase of 105% from the average session volume of 42,170 shares. The stock had previously closed at GBX 265 ($3.43).
MaxCyte Trading Up 8.8 %
The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38. The firm’s 50 day moving average price is GBX 330.71 and its 200 day moving average price is GBX 309.63. The stock has a market capitalization of £324.73 million, a P/E ratio of -9.01 and a beta of 1.13.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
- Five stocks we like better than MaxCyte
- How to Capture the Benefits of Dividend Increases
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is the FTSE 100 index?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
